Posters

Intravitreal aflibercept injection in the treatment of diabetic macular edema in real-life clinical practice: Naïve and switching

Poster Details

First Author: M.Gil Martinez SPAIN

Co Author(s):    M. Rodriguez Cid   M. Fernandez Rodriguez   M. Abraldez Lopez Veiga   F. Gomez-Ulla de Irazazabal                    

Abstract Details



Purpose:

To evaluate the efficacy of intravitreal aflibercept for treatment of diabetic macular edema (DME) in Real-Life Clinical Practice

Setting:

Department of Ophthalmology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.

Methods:

In this retrospective study, 18 DME patients were treated with intravitreal aflibercept with 12 months of follow-up. In our serie we have two groups: Naïve patients (group 1, n=6) and patients with DME previously treated with ranibizumab (Group 2, n=12). We have analysed improvement in best corrected visual acuity and decreased central foveal thickness using optical coherence tomography at 6 and 12 months in both groups.

Results:

Best-corrected visual acuity increased by a mean of 10,47 letters at Month 6 and 8,82 at month 12 in naive patients. Whereas in switching patients best-corrected visual acuity increased by a mean of 10,47 at month 6 and 8,59 at month 12. The proportion of eyes achieving at least a 15-letter improvement from baseline was 38.8% at Month 12. Moreover, the proportion of eyes achieving at least a 10-letter improvement from baseline was 44,4% at month 12. Central macular thickness decreased from 627,12μm to 313 μm at month 6 and 333,06μm at month 12 in Group 1. In Group 2, central macular thickness decreased from 643,82μm to 321,94μm at month 6 and 325,82 at month 12.

Conclusions:

This case series study showed favourable at one year outcomes when using aflibercept to treat DME. Aflibercept provides long-term visual and functional benefits in the treatment of DME in real-life .

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy